Results 71 to 80 of about 22,236,668 (323)

Safety Profiles of Immune Checkpoint Inhibitor Strategies in Gastrointestinal Cancers and Their Association With Clinical Outcomes: A Systematic Review and Meta‐Analysis

open access: yesCancer Medicine
Background Immune checkpoint inhibitors (ICIs) are increasingly used in patients with gastrointestinal cancer (GIC). However, ICI‐associated adverse event (AE) profiles in GIC remain poorly characterized, and whether AE incidence is associated with ...
Jing Lei   +7 more
doaj   +1 more source

Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors

open access: yesImmune Network, 2020
Immune checkpoint inhibitors (ICIs) have been changing the paradigm of cancer treatment. However, immune-related adverse effects (irAEs) have also increased with the exponential increase in the use of ICIs.
Juwhan Choi, Sung-Yong Lee
semanticscholar   +1 more source

Impact of Radiation Therapy on Physical and Psychosocial Health of Adolescents and Young Adults: A Joint Report From the Children's Oncology Group AYA and Radiation Oncology Committees

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Rates of cancer among adolescents and young adults (AYA), age 15–39 years, are increasing. Consequently, radiation oncologists are treating more AYAs who have diagnoses spanning both pediatric and adult practices. Compared to pediatric and older adult patients, AYAs face a unique set of challenges.
Hesham Elhalawani   +7 more
wiley   +1 more source

Comparison of immune checkpoint inhibitors related to pulmonary adverse events: a retrospective analysis of clinical studies and network meta-analysis

open access: yesBMC Medicine
Background Immune checkpoint inhibitors (ICIs) have transformed tumor treatment. However, the risk of pulmonary adverse events (PAEs) associated with ICI combination therapy is still unclear.
Baohui Hong   +6 more
doaj   +1 more source

Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review

open access: yesBritish Journal of Cancer
Immune-related adverse events (irAE) induced by immune checkpoint inhibitors (ICI) are a treatment-limiting barrier. There are few large-scale studies that estimate irAE prevalence.
B. Jayathilaka   +4 more
semanticscholar   +1 more source

Treatment-related Risk of Urologic Adverse Events in Cervical Cancer Survivors

open access: yesUrology
To evaluate the risk of urologic adverse events (UAE), including ureteral complications and urinary fistula, in women treated for cervical cancer to inform clinical decision-making and improve survivorship quality of life.Using the Merative MarketScan database (2011-2021), patients with cervical cancer were identified. Exclusions included
Powell, Jordan   +5 more
openaire   +3 more sources

Grade 1–2 adverse events at least possibly related to study treatment.

open access: yes, 2023
Grade 1–2 adverse events at least possibly related to study treatment.
Lia B. Dimessa-Mbadinga-Weyat (16892314)   +15 more
core   +1 more source

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin   +17 more
wiley   +1 more source

Immune checkpoint inhibitors⁃related nervous system adverse events

open access: yesChinese Journal of Contemporary Neurology and Neurosurgery, 2022
Immune checkpoint inhibitors (ICIs) have been widely used in tumor treatment. Immune⁃related adverse events (irAEs) are common in skin, endocrine, gastrointestinal tract, liver and cardiovascular system symptoms.
WANG Ze⁃yi, LIU Guang⁃zhi
doaj   +1 more source

The Impact of the COVID‐19 Pandemic on Childhood Cancer Survival: A Population‐Based Assessment of Survival Patterns Between 2015 and 2023 in Germany

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Numerous international studies have reported declines in new cancer diagnoses, delayed diagnoses and disruptions in cancer treatment following the implementation of COVID‐19 pandemic public health measures, raising concerns that these effects may ultimately contribute to increased cancer mortality.
Friederike Erdmann   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy